We are deeply saddened by the recent events in both Canada and the United States.  The senseless killing of George Floyd and the countless cases of violence towards minorities is a testament to the systemic racism that pervades our societies. 

We would like to take this moment to stand in solidarity with the families and communities affected by these atrocities.  We also take this moment to add our voice to the countless calls for justice and equality.  Our hope is that our collective voices will serve as a clarion call for immediate change.

In addition, we take this moment to categorically reaffirm our commitment to openness, diversity, and inclusion both broadly and in our workplace as well as to reiterate the importance of our core values.  We strive to build a culture of diversity and inclusion, where everyone feels valued and is treated with dignity and respect.  We do not and will not tolerate prejudice against or marginalization of any group.  We are honored to have the opportunity to work with a diverse group of employees, advisors, investors, and service providers.  We will continue to ensure that we are hiring diverse employees as we know that different ideas, perspectives and backgrounds create a stronger and more creative work environment that delivers better results, a stronger firm, and a better community.  We will remain unflinchingly committed to this effort.

While we certainly don’t possess the answers, we hope that our resolute stand against violence and injustice will contribute to quick and permanent change.

APPROACH

DRI Capital’s strengths as counterparty in royalty monetization transactions include its:

  • Relationship Oriented Approach
  • Breadth of Knowledge
  • Certainty of Deal Execution
  • Access to Capital
LEARN MORE

PORTFOLIO

As a result of these transactions, DRI Capital, through its managed funds, owns royalties on some of the best-selling biopharmaceutical products in the world including:

LEARN MORE

DRI CAPITAL

100 King St. West, Suite 7250
PO Box 62
Toronto, ON M5X 1B1

T: 416-863-1865

APPROACH

DRI Capital’s strengths as counterparty in royalty monetization transactions include its:

  • Relationship Oriented Approach
  • Breadth of Knowledge
  • Certainty of Deal Execution
  • Access to Capital
LEARN MORE

PORTFOLIO

As a result of these transactions, DRI Capital, through its managed funds, owns royalties on some of the best-selling biopharmaceutical products in the world including:

LEARN MORE

DRI CAPITAL

100 King St. West, Suite 7250
PO Box 62
Toronto, ON M5X 1B1

T: 416-863-1865

Investor Relations: